USPTO Examiner MILLER DALE R - Art Unit 1693

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18792077COLON-TARGETED ACTIVE AGENT DELIVERY CARRIER AND USES THEREOFAugust 2024June 2025Allow1030YesNo
18680557AEROSOL AND TOPICAL ADMINISTRATION OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, IN COMBINATION OR SEPARATELY, TO MITIGATE INFECTION BY ENVELOPED VIRUSESMay 2024June 2025Abandon1310NoNo
18609604TREATMENT OF HEARING LOSSMarch 2024October 2024Allow700NoNo
18687295PHARMACEUTICAL COMPOSITIONFebruary 2024March 2025Allow1220YesNo
18424626PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITISJanuary 2024March 2025Allow1321YesNo
18420540METHODS OF SELECTIVELY MODULATING GASTROINTESTINAL MICROBIAL GROWTHJanuary 2024April 2025Allow1520YesNo
18417312LIQUID COMPOSITION COMPRISING GLUCOSEJanuary 2024August 2024Allow700YesNo
18397012COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONSDecember 2023January 2025Abandon1310YesNo
18528550Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorlylase Inhibitors In Combination With RadiationDecember 2023March 2025Allow1510NoNo
18527321GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTSDecember 2023January 2025Abandon1310NoNo
18522850BODY MILKNovember 2023September 2024Allow1020YesNo
18521467PROCESS FOR EFFICIENT CROSS-LINKING OF HYALURONIC ACIDNovember 2023June 2025Allow1920NoNo
18504043NUTRITIONAL COMPOSITIONS WITH MFGM AND CERTAIN HUMAN MILK OLIGOSACCHARIDES AND USES THEREOFNovember 2023February 2025Allow1610YesNo
18555982USE OF CHONDROITIN SULFATE FOR RELIEVING OCULAR PAINOctober 2023March 2025Allow1720YesNo
18378985PERITONEAL DIALYSIS SOLUTIONOctober 2023October 2024Allow1210NoNo
18476119METHODS AND COMPOSITIONS FOR EXTENDING LIFESPANSeptember 2023November 2024Abandon1410NoNo
18237659METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVELAugust 2023November 2024Abandon1410NoNo
18362656COMPOSITE VITAMIN COMPOSITION PROMOTING GASTROINTESTINAL SYSTEM MOTILITYJuly 2023April 2025Allow2110YesNo
18274166CONJUGATES WITH INHIBITORY RECEPTOR LIGANDS TO INDUCE ANERGY IN INSULIN-BINDING B CELLSJuly 2023July 2024Allow1200YesNo
18336419NOVEL PARENTERAL CARBAMAZEPINE FORMULATIONJune 2023October 2024Abandon1610NoNo
18132332ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMDApril 2023February 2025Allow2220YesNo
18131161TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSEApril 2023October 2024Allow1910YesNo
18130475TREATMENT OF ALPHAVIRUS-INDUCED INFLAMMATIONApril 2023January 2025Abandon2210NoNo
18181653NUTRITIONAL COMPOSITION FOR IMPROVING CELL MEMBRANESMarch 2023June 2025Abandon2720NoNo
18176631GLYCOCONJUGATION PROCESSMarch 2023October 2024Allow2010YesNo
17983992COMPOSITIONS COMPRISING AT LEAST ONE N-ACETYLATED AND AT LEAST ONE FUCOSYLATED OLIGOSACCHARIDE FOR USE IN THE PROMOTION OF DIGESTIVE CAPACITY IN INFANTS AND YOUNG CHILDRENNovember 2022September 2024Allow2210NoNo
17804679IMMUNOGENIC COMPOSITIONMay 2022June 2024Allow2520YesNo
17772291ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMDApril 2022January 2025Allow3320NoNo
17765059TREHALOSE FORMULATIONS AND USES THEREOFMarch 2022March 2025Allow3600NoNo
17676675METHOD FOR DEACETYLATION OF BIOPOLYMERSFebruary 2022March 2025Allow3600YesNo
17633869a-GLUCOSIDASE INHIBITOR, INVERTASE INHIBITOR, AND SUGAR ABSORPTION INHIBITORFebruary 2022June 2025Abandon4010NoNo
17586381XYLOOLIGOSACCHARIDE AS A MULTIFUNCTIONAL PREBIOTICJanuary 2022May 2025Abandon4010NoNo
17628857TREATMENT COMPRISING SGLT INHIBITORSJanuary 2022June 2025Abandon4110NoNo
17625394FOOD COMPOSITIONJanuary 2022June 2025Abandon4110NoNo
17615479HUMAN MILK OLIGOSACCHARIDES FOR USE IN THE TREATMENT OF SYMPTOMS IN A PATIENT SUFFERING FROM NON-COELIAC WHEAT AND / OR GLUTEN SENSITIVITYNovember 2021January 2025Abandon3800NoNo
17610951USE OF GINSENOSIDE M1 FOR TREATING CANCERNovember 2021February 2025Abandon3910NoNo
17608837CHLORIDE INTRACELLULAR CHANNEL 1 FOR REGULATION OF FOOD INTAKENovember 2021March 2025Allow4010YesNo
17608203COMPOUND FOR REGULATING BODY WEIGHT IMBALANCE, COMPOSITION THEREOF AND APPLICATION THEREOFNovember 2021January 2025Allow3910NoNo
17606313NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASESOctober 2021January 2025Allow3910YesNo
17506227GLUCOSE INFUSION SOLUTION COMPOSITIONOctober 2021June 2025Allow4340NoNo
17472604AEROSOL AND TOPICAL ADMINISTRATION OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, IN COMBINATION OR SEPARATELY, TO MITIGATE INFECTION BY ENVELOPED VIRUSESSeptember 2021April 2024Allow3140YesNo
17435629METHOD AND KIT FOR DETECTING INFLUENZA VIRUS, AND METHOD FOR DIAGNOSING INFLUENZA VIRUS INFECTIONSeptember 2021April 2025Allow4310NoNo
17419068BRAIN-PENETRATING LIGAND AND DRUG CARRIERJune 2021October 2024Allow4010YesNo
17418570HEAT STRESS RELIEVING AGENTJune 2021April 2025Abandon4620NoNo
17417049COMPOSITION AND METHOD FOR PROMOTING INTESTINAL BARRIER HEALINGJune 2021November 2024Abandon4110NoNo
17292963CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNAMay 2021February 2025Allow4510YesNo
17291481METHODS OF SUPPORTING GASTROINTESTINAL HOMEOSTASISMay 2021November 2024Allow4210YesNo
17286803PHARMACEUTICAL USE OF ANEMOSIDE B4 AGAINST ACUTE GOUTY ARTHRITISApril 2021January 2025Allow4520NoNo
17285675USE OF SGLT2 INHIBITORS TO TREAT PRIMARY SCLEROSING CHOLANGITISApril 2021June 2025Abandon5020NoNo
17281598Dietary fiber for treating patients suffering from methylmalonic acidemia and propionic acidemiaMarch 2021December 2024Allow4511YesNo
17278467TARGETED DRUG DELIVERY SYSTEM TO BE USED IN TREATING OSTEOMYELITISMarch 2021December 2024Abandon4511NoNo
17277534CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONMarch 2021September 2024Allow4210YesNo
17268655TREATMENT FOR GENE REACTIVATIONFebruary 2021November 2024Allow4520NoNo
17267538CELLULOSE ACETATE COMPOSITION AND MOLDED ARTICLEFebruary 2021November 2024Abandon4520NoNo
17259013Pharmaceutical Composition for Preventing or Treating Cancer, Comprising Gossypol, Phenformin, and Anticancer AgentJanuary 2021May 2024Allow4010NoNo
17251493Application Of Xylan In The Preparation Of Drugs Or Food For Preventing Or Treating OsteoporosisJanuary 2021December 2024Abandon4820YesNo
17253781ANTI-RETROVIRAL THERAPIES AND REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASEDecember 2020October 2024Allow4621NoNo
17058562LIPID-MODIFIED NUCLEIC ACID COMPOUNDS AND METHODSNovember 2020June 2025Abandon5511NoNo
17055446METHOD OF TREATING MALIGNANT TUMOR BY AZABICYCLIC COMPOUNDNovember 2020March 2024Allow4010NoNo
17049646NOVEL MOGROSIDES, METHODS OF OBTAINING THE SAME, AND USESOctober 2020June 2024Allow4400YesNo
17041175NOVEL SAPONIN ADJUVANT AND EVALUATION METHOD THEREOFSeptember 2020November 2024Allow5021NoNo
17018975VACCINE SYSTEM FOR VACCINE ADJUVANTSeptember 2020April 2022Abandon1960NoNo
16984626PREPARATION METHOD OF 4D CHITOSAN-BASED THERMOSENSITIVE HYDROGELAugust 2020January 2025Allow5450YesNo
16053354DRUG COMPOUND AND PURIFICATION METHODS THEREOFAugust 2018September 2019Allow1400YesNo
15771941PHARMACEUTICAL COMPOSITION, USE OF MEFLOQUINE IN A FIXED DOSE, AND METHOD FOR TREATING TUBERCULOSISApril 2018February 2020Allow2220NoNo
15579481THERAPEUTIC AGENT FOR DRY EYE CHARACTERIZED BY BEING APPLIED TO EYE OF DRY EYE PATIENT WEARING SOFT CONTACT LENSDecember 2017April 2020Allow2820YesNo
15575787ANTICANCER ADJUVANT CONTAINING PANAXADIOL GINSENOCIDE COMPOUNDNovember 2017August 2019Allow2120NoNo
15564994GLYCOSAMINOGLYCAN ESTERS, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN FORMULATIONS FOR OPHTHALMIC USEOctober 2017February 2019Allow1610YesNo
15129149Solid Composition Comprising Amorphous SofosbuvirSeptember 2016August 2019Allow3421YesNo
15123359HYALURONIC ACID MODIFIED BY SPHINGOSINE-1-PHOSPHORIC ACIDSeptember 2016June 2019Allow3330YesNo
14785814AQUEOUS OPHTHALMIC FORMULATIONS BASED ON AZITHROMYCINOctober 2015February 2019Allow4030NoNo
14780423GLYCOGEN-BASED WATER SOLUBILITY ENHANCERSSeptember 2015February 2020Allow5260YesNo
14758589ALGINATE COMPOSITIONS AND USES THEREOFJune 2015August 2019Allow5040YesNo
14162253Phenolic Coatings and Methods of Making and Using SameJanuary 2014August 2018Allow5560YesNo
13515152N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOFSeptember 2012August 2018Allow6041YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MILLER, DALE R.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
1.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MILLER, DALE R - Prosecution Strategy Guide

Executive Summary

Examiner MILLER, DALE R works in Art Unit 1693 and has examined 68 patent applications in our dataset. With an allowance rate of 69.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner MILLER, DALE R's allowance rate of 69.1% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MILLER, DALE R receive 1.71 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MILLER, DALE R is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +44.9% benefit to allowance rate for applications examined by MILLER, DALE R. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 35.7% of applications are subsequently allowed. This success rate is in the 76% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 45.5% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 92% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.